Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

February 5, 2016 by Alan Khadavi

Tiotropium for Asthma

Tiotropium is a once daily long acting anti-cholinergic bronchodilator.  Tiotropium has demonstrated efficacy as on add therapy in patients with asthma who were symptomatic despite using medium to high dose inhaled corticosteroids.  Current asthma guidelines recommend using a long acting beta-agonist for asthmatic patients uncontrolled with inhaled steroids.  Other controller options are the addition of Singulair or theophylline.  However, some patients do not respond to these agents.  Recent studies on Tiotropium (Respimat) have looked in to see if there was some benefit of using this as add on therapy for asthma patients.

A recent study published in the Journal of Allergy and Clinical Immunology evaluated using Tiotropium as add on therapy to low to medium dose inhaled inhaled corticosteroids for adults with symptomatic asthma.  The study of Tiotropium was compared to placebo (not a long acting beta agonist such as salmeterol or formoterol).

Adults with symptomatic asthma who were not controlled low to medium dose inhaled corticosteroids were randomized to either receive Tiotropium or placebo.  After 12 weeks, the patients in the Tiotropium treatment did better on their pulmonary function testing (spirometry).  Adverse event were comparable between the Tiotropium group and the placebo group.

The conclusion of the study was that Tiotropium was an efficacious bronchodilator when added to low to moderate inhaled steroids in a population of adult patients not fully controlled who have mild to moderate asthma.  Once daily Tiotropium improved lung function after 12 weeks of treatment.  Tiotropium may be an efficacious add on therapy when added to inhaled steroids in patients who have inadequately controlled asthma.

We are currently seeing an influx of new asthma medications out for patients poorly controlled.  Recently to come on the market is Nucala https://allergylosangeles.com/allergy-blog/new-asthma-drug-nucala-mepolizumab-for-severe-eosinophilic-asthma/ and there are many more studies underway for future and emerging therapies https://allergylosangeles.com/allergy-blog/new-asthma-medications/  For patients who can not afford the newer biologics or who do not want to take them, Tiotropium may be an alternative add on treatment option for certain patients who do not respond to inhaled long acting beta agonists that are found in medications such as Advair, Dulera, Symbicort or Breo.

There are a plethora of treatment options for patients who have uncontrolled asthma, please see your asthma or allergy doctor if your asthma is not well maintained and he/she will discuss with you what your best option may be.

Filed Under: Asthma, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page